Albert Einstein College of Medicine Supports New CME Website Dedicated to Prostate Cancer

Needham, MA (PRWEB) July 19, 2016

Prostate cancer is the most common and fifth-leading cause of death from cancer in men. In 2014 alone, an estimated 233,000 cases were diagnosed. And, while almost 90% of cases are caught early with prostate-specific antigen (PSA) screening, up to 40% will still develop metastases and worsen despite advancing treatment options. Clinical challenges, such as optimal sequences of therapies and ideal combinations of therapies, can often hinder results.

To help save lives, PlatformQ Health is launching a new online education platform, VirtualProstateSummit.com, with complimentary CME-accredited programs for clinicians involved in the management of patients with prostate cancer. The new event platform kicks off with Evolving Treatment Paradigms in Metastatic Castration-Resistant Prostate Cancer, held on July 27th, 2016 from 10am to noon EST.

"The field of prostate cancer therapeutics is rapidly changing with the development of new hormonal therapies, radiopharmaceuticals, immune therapies, and novel chemotherapies for metastatic disease," says Dr. Andrew Armstrong. "In addition, precision medicine approaches in biomarker defined populations are likely to change the practice of medicine in this disease in the near future. This two-part CME program will�provide an update in the treatments of men with hormone-sensitive and castration-resistant prostate cancer, and discuss both standard and new investigational approaches to treating this disease."

This inaugural program will be presented by faculty from Duke University including Director of Genitourinary Medical Oncology Daniel J. George, MD and Associate Professor of Medicine and Surgery Andrew J. Armstrong, MD. Medical oncologist, urologists and other healthcare professionals treating prostate cancer can register here.

"Online continuing education is being adopted in every field, but offers particular advantages to busy doctors that need the most up-to-date information," said Robert Rosenbloom, Co-Founder and CEO of PlatformQ Health. "Prostate cancer impacts so many lives and we are thrilled to offer VirtualProstateSummit as a hub for exchanging knowledge to battle this prolific disease."

At the conclusion of this activity, participants will be able to:

• Address barriers to the optimal use of new therapies in patients with prostate cancer
• Evaluate relative safety, efficacy, and tolerability on therapeutic options for prostate cancer and potential sequencing combinations for those patients with suboptimal responses
• Address barriers to the optimal use of new therapies in patients with prostate cancer
• Identify and assess relative safety, efficacy, and tolerability on therapeutic options for metastatic castration-resistant prostate cancer

Health care professionals can sign up for the event here.

The activity has been planned and implemented in accordance with requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Albert Einstein College of Medicine and Montefiore Medical Center and PlatformQ Health Education, LLC. The Albert Einstein College of Medicine and Montefiore Medical Center is accredited by the ACCME to provide continuing medical education for physicians.

Read the full story at http://www.prweb.com/releases/2016/07/prweb13560943.htm

You May Also Be Interested In

• Needham Reiterates Buy Rating on Amazon.com (AMZN), Raises Estimates
• Carnival Corporation & plc Announces Pricing of €500 Million 5.75% Senior Unsecured Notes Offering for Refinancing and Interest Expense Reduction and Successful Repricing of Senior Secured First
• Eaton to announce first quarter 2024 earnings on April 30, 2024